Literature DB >> 17467140

Transcriptional signatures in Huntington's disease.

Jang-Ho J Cha1.   

Abstract

While selective neuronal death has been an influential theme in Huntington's disease (HD), there is now a preponderance of evidence that significant neuronal dysfunction precedes frank neuronal death. The best evidence for neuronal dysfunction is the observation that gene expression is altered in HD brain, suggesting that transcriptional dysregulation is a central mechanism. Studies of altered gene expression began with careful observations of postmortem human HD brain and subsequently were accelerated by the development of transgenic mouse models. The application of DNA microarray technology has spurred tremendous progress with respect to the altered transcriptional processes that occur in HD, through gene expression studies of both transgenic mouse models as well as cellular models of HD. Gene expression profiles are remarkably comparable across these models, bolstering the idea that transcriptional signatures reflect an essential feature of disease pathogenesis. Finally, gene expression studies have been applied to human HD, thus not only validating the approach of using model systems, but also solidifying the idea that altered transcription is a key mechanism in HD pathogenesis. In the future, gene expression profiling will be used as a readout in clinical trials aimed at correcting transcriptional dysregulation in Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17467140      PMCID: PMC2449822          DOI: 10.1016/j.pneurobio.2007.03.004

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  172 in total

1.  Evaluating test statistics to select interesting genes in microarray experiments.

Authors:  Charles Kooperberg; Simonetta Sipione; Michael LeBlanc; Andrew D Strand; Elena Cattaneo; James M Olson
Journal:  Hum Mol Genet       Date:  2002-09-15       Impact factor: 6.150

Review 2.  The postsynaptic density at glutamatergic synapses.

Authors:  M B Kennedy
Journal:  Trends Neurosci       Date:  1997-06       Impact factor: 13.837

3.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

4.  Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.

Authors:  S W Davies; M Turmaine; B A Cozens; M DiFiglia; A H Sharp; C A Ross; E Scherzinger; E E Wanker; L Mangiarini; G P Bates
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

5.  Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease.

Authors:  S J Augood; R L Faull; P C Emson
Journal:  Ann Neurol       Date:  1997-08       Impact factor: 10.422

6.  Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.

Authors:  Ruth Luthi-Carter; Sarah A Hanson; Andrew D Strand; Donald A Bergstrom; Wanjoo Chun; Nikki L Peters; Annette M Woods; Edmond Y Chan; Charles Kooperberg; Dimitri Krainc; Anne B Young; Stephen J Tapscott; James M Olson
Journal:  Hum Mol Genet       Date:  2002-08-15       Impact factor: 6.150

7.  Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

Authors:  Edmond Y W Chan; Ruth Luthi-Carter; Andrew Strand; Steven M Solano; Sarah A Hanson; Molly M DeJohn; Charles Kooperberg; Kathryn O Chase; Marian DiFiglia; Anne B Young; Blair R Leavitt; Jang-Ho J Cha; Neil Aronin; Michael R Hayden; James M Olson
Journal:  Hum Mol Genet       Date:  2002-08-15       Impact factor: 6.150

8.  Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects.

Authors:  Ruth Luthi-Carter; Andrew D Strand; Sarah A Hanson; Charles Kooperberg; Gabriele Schilling; Albert R La Spada; Diane E Merry; Anne B Young; Christopher A Ross; David R Borchelt; James M Olson
Journal:  Hum Mol Genet       Date:  2002-08-15       Impact factor: 6.150

9.  Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice.

Authors:  Elisa Fossale; Vanessa C Wheeler; Vladimir Vrbanac; Lori-Anne Lebel; Allison Teed; Jayalakshmi S Mysore; James F Gusella; Marcy E MacDonald; Francesca Persichetti
Journal:  Hum Mol Genet       Date:  2002-09-15       Impact factor: 6.150

10.  Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses.

Authors:  Simonetta Sipione; Dorotea Rigamonti; Marta Valenza; Chiara Zuccato; Luciano Conti; Joel Pritchard; Charles Kooperberg; James M Olson; Elena Cattaneo
Journal:  Hum Mol Genet       Date:  2002-08-15       Impact factor: 6.150

View more
  106 in total

Review 1.  Neuroinflammation in Huntington's disease.

Authors:  Thomas Möller
Journal:  J Neural Transm (Vienna)       Date:  2010-06-10       Impact factor: 3.575

Review 2.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

3.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

4.  Regulation of RE1 protein silencing transcription factor (REST) expression by HIP1 protein interactor (HIPPI).

Authors:  Moumita Datta; Nitai P Bhattacharyya
Journal:  J Biol Chem       Date:  2011-08-06       Impact factor: 5.157

5.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Vasanth Pappu; Bruce Fischl; Doug Greve; Nathanael Hevelone; Steven M Hersch
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

Review 6.  Epigenetic principles and mechanisms underlying nervous system functions in health and disease.

Authors:  Mark F Mehler
Journal:  Prog Neurobiol       Date:  2008-10-17       Impact factor: 11.685

Review 7.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

8.  Huntington's disease pattern of transcriptional dysregulation in the absence of mutant huntingtin is produced by knockout of neuronal GLT-1.

Authors:  Robert B Laprairie; Geraldine T Petr; Yan Sun; Kathryn D Fischer; Eileen M Denovan-Wright; Paul A Rosenberg
Journal:  Neurochem Int       Date:  2018-04-27       Impact factor: 3.921

Review 9.  Modeling Huntington's disease with induced pluripotent stem cells.

Authors:  Julia A Kaye; Steven Finkbeiner
Journal:  Mol Cell Neurosci       Date:  2013-02-28       Impact factor: 4.314

10.  Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease.

Authors:  Eduardo E Arteaga-Bracho; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Jenna R Petronglo; Alicia D Zambrano; Julio Inocencio; Chirstopher D De Jesus; Joseph O Louie; Solen Gokhan; Mark F Mehler; Aldrin E Molero
Journal:  Neurobiol Dis       Date:  2016-09-10       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.